Grass Pollen Allergy
3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AllergopharmaGermany - Reinbek
3 programs2
1
grass pollen allergen extractPhase 4
Grass pollen formulationPhase 31 trial
grass pollen allergoidPhase 3
Active Trials
Innovation PharmaceuticalsMA - Wakefield
1 programMotivation-enhancing interventionN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AllergopharmaGrass pollen formulation
Innovation PharmaceuticalsMotivation-enhancing intervention
Clinical Trials (2)
Total enrollment: 384 patients across 2 trials
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
Start: Feb 2003Est. completion: Sep 2011160 patients
Phase 3Completed
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
Start: Sep 2022Est. completion: Jun 2024224 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.